光敏化剂血卟啉(Hp)及其衍生物(HpD),近年来已作为新型抗肿瘤药物应用于临床,然而其对肿瘤组织的选择性作用不十分理想,对肿瘤周围及其它正常组织也有损伤。为增强其特异性改进杀伤肿瘤效果,我们选择抗人T淋巴细胞MCAB作为HP的特异载体,制备出MCAB-Hp的杂交分子,这种杂交分子兼备二者的特点,在体外对T细胞性白血病细胞有选择性杀伤,从而表明这类杂交分子在肿瘤治疗中的潜力。 Photosensitizers Hematoporphyrin (Hp) and its derivatives (HpD) have been used clinically as novel antitumor drugs in recent years. However, their selective effects on tumor tissues are not very satisfactory. They also have on the periphery of tumors and other normal tissues. damage. In order to enhance its specificity to improve the killer tumor effect, we chose anti-human T lymphocyte MCAB as a specific vector of HP to prepare a hybrid molecule of MCAB-Hp. This hybrid molecule has the characteristics of both, in vitro T cell leukemia The cells selectively kill, indicating the potential of this class of hybrid molecules in cancer therapy.